Abstract

A malleable sustained release formulation is created utilizing a local anesthetic wherein the composition is made sustained release by incorporating it into a bovine or porcine hemostatic agent. The composition is malleable enough to fit into a cavity such as a dental cavity and form the shape of the cavity. In addition to providing sustained release of the anesthetic, the composition also provides quicker reduction in bleeding.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/06 - OintmentsBases therefor
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61P 23/02 - Local anaesthetics

Abstract

A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

Abstract

A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

Abstract

A malleable sustained release formulation is created utilizing a local anesthetic wherein the composition is made sustained release by incorporating it into a bovine or porcine hemostatic agent. The composition is malleable enough to fit into a cavity such as a dental cavity and form the shape of the cavity. In addition to providing sustained release of the anesthetic, the composition also provides quicker reduction in bleeding.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/06 - OintmentsBases therefor
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61P 23/02 - Local anaesthetics

Abstract

A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

Abstract

A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61P 23/02 - Local anaesthetics
• A61L 15/00 - Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61K 9/70 - Web, sheet or filament bases
• A61L 15/44 - Medicaments

Goods & Services

Research and development in the field of pain management; research and development in the field of sustained drug delivery; research and development in the field of drug encapsulation; research and development in the field of dental and oral surgery devices; research and development in the field of combination medical devices; research and development in the field of targeted drug therapy; pharmaceutical research and development; research and development in the field of micro-compounding; research and development in the field of pharmacokinetics; Providing research information in the field of pain management, sustained drug delivery, drug encapsulation, and dental and oral surgery devices

Abstract

The present invention is a malleable controlled release anesthetic combined with a hemostatic for packing in body cavity such as dental extraction cavity, a wound cavity or a surgical cavity.

IPC Classes  ?

• A61L 15/32 - Proteins, polypeptidesDegradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
• A61L 15/44 - Medicaments
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents

Abstract

A malleable sustained release formulation is created utilizing a local anesthetic wherein the composition is made sustained release by incorporating it into a bovine or porcine hemostatic agent. The composition is malleable enough to fit into a cavity such as a dental cavity and form the shape of the cavity. In addition to providing sustained release of the anesthetic, the composition also provides quicker reduction in bleeding.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/06 - OintmentsBases therefor
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61P 23/02 - Local anaesthetics

Abstract

The present invention relates to a method of delivering local anesthetic after dental extraction surgery. The present invention relates to packing the tooth socket with a tinned release local anesthetic which is coordinated with an initial local anesthetic and which lasts up to 5 days. The socket can be surgically sealed or the implant can act as the sealing means.

IPC Classes  ?

• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61P 23/02 - Local anaesthetics